IRIDEX Corporation — Q2 2015 Form 10-Q
Business and period: IRIDEX develops, manufactures and sells ophthalmic laser systems, delivery devices, consumables and related services. The company reports one segment, ophthalmology. This filing covers the 13 weeks ended July 4, 2015, and the six-month year-to-date period; comparisons are with the corresponding 2014 periods.
Financial performance and position
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $9.03m | $10.59m | $19.83m | $20.92m |
| Gross profit / margin | $4.22m / 46.7% | $5.30m / 50.0% | $9.63m / 48.6% | $10.36m / 49.5% |
| Operating income (loss) | ($0.75m) | $0.40m | ($0.34m) | $1.00m |
| Net income (loss) | ($0.65m) | $0.30m | ($0.41m) | $0.78m |
| Net income (loss) per diluted share | ($0.07) | $0.03 | ($0.04) | $0.07 |
- Cash flow: Year-to-date operating cash flow was $0.39m, down from $1.42m. Investing used $0.82m, including $0.59m for property and equipment and $0.24m in earn-out payments. Financing used $0.66m; this included $0.67m for share repurchases and $0.61m of payroll taxes on net-settled equity awards, partly offset by $0.61m from option exercises.
- Liquidity and debt: Cash and cash equivalents were $12.20m at July 4, versus $13.30m at January 3; working capital was $24.9m, versus $25.9m. The filing reports no outstanding interest-bearing debt. Total liabilities were $7.94m, including a $1.22m acquisition earn-out liability.
- Other balance-sheet items: Inventory rose to $10.17m from $9.12m. Total assets were $41.17m and stockholders’ equity was $33.23m.
Changes versus prior comparable periods
- Q2 revenue fell 14.7%; year-to-date revenue fell 5.2%. Q2 system revenue declined domestically and internationally, while recurring revenue was essentially flat at $4.78m. Year-to-date recurring revenue grew 3.9% to $10.00m, but system sales declined.
- Management attributed lower system sales to production difficulties that developed into quality issues as the company increased output. It reduced shipments, particularly to international distributors. A stronger U.S. dollar also continued to weigh on international system sales.
- Q2 gross margin contracted 3.3 percentage points; year-to-date margin contracted 0.9 points. Management said operating costs remained relatively steady as revenue declined. Year-to-date operating expenses increased 6.6%, driven mainly by R&D and sales and marketing spending.
- U.S. revenue was 59.7% of Q2 sales and 55.3% of year-to-date sales. International sales represented 40.3% of Q2 revenue.
Outlook, risks and notable items
- Management stated that cash and expected operating cash generation should provide sufficient liquidity for the next 12 months. The filing provides no quantified revenue, earnings or margin guidance.
- Management expects gross margins to fluctuate with geography and product mix, manufacturing variances, production efficiency and other factors. The company launched its Cyclo G6 glaucoma platform in the U.S. in February 2015, aiming to expand both console and recurring procedural sales.
- The principal near-term risk highlighted is production and product quality: unresolved issues could further constrain shipments, raise costs and harm customer acceptance. Other disclosed risks include international distributor dependence, currency-related competitiveness, competition, regulatory requirements, reimbursement uncertainty, suppliers and product defects.
- Contractual obligations totaled $10.63m, including $9.05m of purchase commitments and $1.58m of operating leases; $8.25m was due within one year. The company reported no material off-balance-sheet arrangements.
- The board extended the stock repurchase program in August 2015 and authorized an additional $2.0m. At July 4, approximately $0.2m remained under the existing authorization.
- Other items to note: the company had $0.9m of unrecognized tax benefits; goodwill was not impaired in its Q2 annual test. Management reported effective disclosure controls and no material change in internal control over financial reporting. Ordinary-course legal matters were not expected to have a material adverse effect.
Important facts for investors to verify
- Whether production and quality problems have been corrected, and whether system shipments and gross margins recover.
- Whether international sales stabilize despite currency pressure and distributor-related risks, and whether recurring revenue growth continues.
- Whether cash generation remains adequate given the operating loss, inventory increase, purchase commitments and ongoing repurchases.
- How the Cyclo G6 launch performs commercially, including adoption and recurring probe sales.
- The filing’s balance sheet reports 10,019,871 shares outstanding at July 4, while the cover page reports 9,998,480 at July 24; verify the subsequent share-count movement and repurchases.